Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cimavax egf
- Development stage
- Phase 3
- Lead developer
- Center for Molecular Immunology
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
CIMAvax-EGF is a therapeutic cancer vaccine developed to treat non-small cell lung cancer (NSCLC). It consists of recombinant human epidermal growth factor (EGF) chemically conjugated to the P64 protein from *Neisseria meningitidis* and formulated with Montanide ISA 51 as an adjuvant. The vaccine works by inducing the patient's immune system to produce antibodies against EGF, thereby depleting circulating EGF levels in the blood. This prevents EGF from binding to its receptor (EGFR) on cancer cells, effectively "starving" them of a key growth and survival signal and inhibiting tumor proliferation. CIMAvax-EGF does not directly kill cancer cells but blocks their ability to grow by neutralizing an essential growth factor. It was developed at the Center for Molecular Immunology in Havana, Cuba, and is approved for use in Cuba as maintenance therapy for advanced NSCLC after chemotherapy.
- Brand names
- CimaVax-EGFCIMAVAX
- Other names
- recombinant human EGF-rP64K/montanide ISA 51 vaccine
02
Targets
Beyond the preview
Go deeper on cimavax egf.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cimavax egf.